Abstract
Background: COVID-19 has become a global pandemic. Studies about
SARS-CoV-2 co-infection with influenza A virus (IAV) in the influenza
season will contribute to the antiviral interventions of co-infected
patients. Methods: A cohort of 145 COVID-19 patients in Wuhan union
hospital were reviewed and we found 2 patients were co-infected with
both SARS-CoV-2 and IAV. Then we searched from PubMed, Web of Science
and CNKI with combinations of the following key words: “COVID-19,
SARS-COV-2, influenza A and co-infection” from January 1 up to May 1,
and 6 studies were included in this descriptive analysis. Results: Of
the 13 co-infected patients, 2 were from Wuhan union hospital, another
11 were collected from the reports published on PubMed, Web of Science
and CNKI. Of the 13 patients, the median age was 50 years (IQR,
40.5-67.5). Among the 13 patients, 7 (53.8%) were severe types, 7 were
males and 5 had comorbidities. The most common symptoms among the 13
patients were cough (100%), fever (92.3%) and dyspnea (76.9%). 8
patients had lymphocytopenia on admission and all the 13 patients had
abnormal radiological changes in their first examination after
admission. The median time from symptom onset to hospital admission was
4.5 days (IQR, 2.75-5.5), and the median time of hospital stay was 17
days (IQR,15-20). 7 patients were discharged, and the clinical outcomes
of the remaining 6 patients were unclear. Conclusion: Patients with both
SARS-COV-2 and IAV infection showed similar changes in symptoms and
radiological images with patients infected with SARS-COV-2 only.
SARS-COV-2 co-infection with IAV can lead to more severe clinical
condition but had similar hospital stay compared with patients infected
with SARS-COV-2 only in the fast review.